title: Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?
abstract: Data from well-designed, prospective clinical trials are lacking to support treatment of primary tumor in men diagnosed with metastatic prostate cancer. However, a growing body of evidence suggests that treatment of the primary tumor may enhance cancer control and survival in some men. This evidence is examined and recommendations are made for identifying patients with metastatic prostate cancer who may benefit from definitive treatment of the prostate tumor.
authors.affiliation: Department of Urology, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. canbyhagino@uthscsa.edu
authors.forename: Edith D
authors.initials: ED
authors.lastname: Canby-Hagino
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Swanson
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.forename: Joseph W
authors.initials: JW
authors.lastname: Basler
authors.forename: Javier
authors.initials: J
authors.lastname: Hernandez
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018450:Disease Progression; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists